Julie Schanz

Julie Schanz

Auto-generated profile, based on publicly available information

Julie Schanz

Universitätsmedizin Göttingen

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 March 2018 in Blood Cancer Journal
Verified
Journal Article
Open access
PDF file
JSJulie Schanz
Julie Schanz
NCNaciye Cevik
Naciye Cevik
CFChrista Fonatsch
Christa Fonatsch
FBFriederike Braulke
Friederike Braulke
KSKatayoon Shirneshan
Katayoon Shirneshan
DHDetlef Haase
Detlef Haase
Clonal cytogenetic evolution (CE) (i.e., acquisition of new chromosomal aberrations over time) is relevant for the progression of myelodysplastic syndromes (MDS). We performed detailed analysis of CE in 729 patients with MDS and related disorders. Patients with CE showed shorter survival (median OS 18.0 versus 53.9 months; P < 0.01), higher leukemic transformation rate (48.0% versus 21.4%; P < 0.01) and shorter intervals to leukemic transformation (P < 0.01). Two main CE patterns were detected: early versus late CE (median onset 5.3 versus 21.9 months; P < 0.01) with worse survival outcomes for early CE. In the case of CE, del (7q)/−7 (P = 0.020) and del (17p) (P = 0.002) were especially unfavorable. Extending the evolution patterns from Tricot et al. (1985) forming five subgroups, prognosis was best (median OS not reached) in patients with “transient clones/changing clone size”, whereas those with “CE at diagnosis” showed very poor outcomes (P < 0.01 for comparison of all). Detailed sequential cytogenetic analysis during follow-up improves prognostication in MDS patients and acknowledges the dynamic biology of the disease. Evidence, time-point, and patterns of cytogenetic clonal evolution should be included into future prognostic scoring systems for MDS.

17 April 2019 in Genes, Chromosomes and Cancer
Verified
Journal Article
Closed access
PDF file
CGChristina Ganster
Christina Ganster
CMCatharina Müller‐Thomas
Catharina Müller‐Thomas
CHClaudia Haferlach
Claudia Haferlach
CSCorinna Strupp
Corinna Strupp
KOKiyoyuki Ogata
Kiyoyuki Ogata
DHDetlef Haase
Detlef Haase


12 October 2022 in Viruses
Verified
Journal Article
Open access
PDF file
SDSascha Dierks
Sascha Dierks
KTKarin Thiele
Karin Thiele
WBWolfgang Bohne
Wolfgang Bohne
RLRaimond Lugert
Raimond Lugert
MWMichael Weig
Michael Weig
MSMoritz Schnelle
Moritz Schnelle
In SARS-CoV-2 diagnostics, cycle threshold (Ct) values from qRT-PCRs semi-quantitatively estimate a patient’s viral load. However, relevant analytical differences between qRT-PCR assays are often neglected. This study was designed (i) to identify such differences between five commonly used assays and (ii) to demonstrate a straightforward strategy to harmonize them. QRT-PCRs for SARS-CoV-2 were carried out in 85 oropharyngeal swab samples using three fully automated (Alinity m, cobas®6800 and GeneXpert) and two semi-automated (genesig® and RIDA®GENE) assays. Qualitative results (positive/negative) showed excellent comparability between the fully automated assays, but not between the Alinity m and semi-automated methods. Ct values significantly varied between all the methods, with the median values ranging from 22.76 (Alinity m) to 30.89 (RIDA®GENE) and 31.50 (genesig®), indicating the lowest sensitivity for semi-automated methods. Passing–Bablok analysis further revealed systemic biases. Assay-specific viral load concentration calculations—based on generated individual standard curves—resulted in much better comparability between the assays. Applying these calculations, significant differences were no longer detectable. This study highlights relevant analytical differences between SARS-CoV-2 qRT-PCR assays, leading to divergent decisions about the mandatory isolation of infected individuals. Secondly, we propose a strategy to harmonize qRT-PCR assays to achieve better comparability. Our findings are of particular interest for laboratories utilizing different assays.

24 September 2018 in Genes, Chromosomes and Cancer
Verified
Journal Article
Closed access
PDF file
JSJulie Schanz
Julie Schanz
FSFrancesc Solé
Francesc Solé
MMMar Mallo
Mar Mallo
ELElisa Luño
Elisa Luño
JCJose Cervera
Jose Cervera
DHDetlef Haase
Detlef Haase

6 July 2021 in Journal Of Nephrology
Verified
Journal Article
Closed access
PDF file
SHSamy Hakroush
Samy Hakroush
LLLuca-Yves Lehnig
Luca-Yves Lehnig
MWManuel Wallbach
Manuel Wallbach
JSJulie Schanz
Julie Schanz
MKMichael Koziolek
Michael Koziolek